Turning continuous wearable data into earlier clinical trial insight
LONGITUDINAL is developing decision intelligence for wearable-enabled clinical trials
We are developing a platform to support CROs and pharma sponsors in translating continuous data from wearable and connected devices into clearer operational and clinical insight between patient visits. Our initial focus is on use cases relevant to Phase II and Phase III trials, where earlier visibility into adherence, tolerability, physiological response and patient burden could improve how studies are designed, monitored and executed.
A continuous data decision platform enabling CROs to win, execute and innovate in trials
Clinical trials generate more data than ever. The decision gap remains.
Wearables and sensors are becoming part of modern clinical trials, but continuous data is still often fragmented, specific to individual studies and difficult to convert into operational actions. The challenge is no longer only collecting data. The challenge is knowing what the data means, when it matters, and how it should inform trial decisions.
Between scheduled visits, important signals can be missed:
Early physiological or tolerability changes
Adherence issues
Increasing patient burden
Patterns linked to dropout risk
Response differences between patient groups
LONGITUDINAL is being built to address these decision gaps.
From continuous data to trial insight that can inform earlier decisions
LONGITUDINAL is being developed to help trial teams move from data capture to decision support. Our current development work is focused on turning continuous wearable data and trial context into structured insight that can support CRO and sponsor decision-making.
We do not build devices - We do not run trials - We do not replace existing clinical trial systems.
Our aim is to help clinical development teams make better use of the continuous data already becoming part of modern trials, within existing workflows.
Building decision intelligence for smarter, faster and more valuable clinical trial decisions
LONGITUDINAL is focusing on three high-value decision areas relevant to to later-stage clinical development.
Earlier insight into patient behaviour, burden and response can support smarter trial design and reduce avoidable complexity.
Protocol optimisation
Continuous data can provide earlier visibility into signals that may support development decisions before traditional endpoints are fully available.
Go / no-go confidence
Longitudinal patterns can help identify differences in response, tolerability and patient experience that may not be visible through scheduled visits alone.
Patient stratification
Being developed with CRO and pharma sponsor workflows in mind
LONGITUDINAL is being developed to help CROs explore how continuous data could enable earlier decisions that strengthen trial execution, sponsor value and differentiation.
For CROs
LONGITUDINAL is being shaped to help sponsors gain earlier insight into patient response, burden and adherence, supporting more informed development decisions.
For pharma sponsors
LONGITUDINAL is building a scalable decision intelligence platform in a market where continuous data is becoming increasingly relevant, but remains underused in clinical trial decision-making.
For investors
Built from clinical trial insight, not technology assumptions
LONGITUDINAL has been shaped through market validation, expert input and analysis of wearable-enabled clinical studies. We listened to clinical development, clinical operations, CROs and digital health experts.
We listened to clinical development, clinical operations, CROs and digital health experts.
We have engaged with experienced pharma technology development and clinical trial workflow specialists to guide development priorities.
We analysed hundreds of clinical studies where wearable and sensor devices were used and reviewed how continuous data was applied.
We have built leadership and an advisory team bringing expertise across life sciences, clinical development, data science, digital health, finance and scale-up.
This work has reinforced a consistent conclusion: the industry does not need more disconnected data. It needs continuous data translated into decisions.
Interested in continuous data for clinical trial decisions?
We are interested in speaking with CROs, pharma sponsors, clinical development teams, technology partners and investors exploring how continuous data could improve clinical trial decision-making.
